OnCore Biopharma Inc. is buying Enantigen Therapeutics Inc. for an undisclosed amount.
Doylestown, Pennsylvania, Enantigen is a pharmaceutical company that is working on developing medicines that inhibit an s-antigen secretion, a process related to immune response, and another that aims to stop capsid assembly, or the production of virus particles.
OnCore, also headquartered in Doylestown, focuses on developing treatments for hepatitis B.
Enantigen says the acquisition should allow its advance its programs into human clinical trials. OnCore plans to add the programs to its drug candidates to advance multiple combinations of drugs into human clinical trials, the company says.
Other recent drug deals include Johnson & Johnson's (NYSE: JNJ) purchase of Alios BioPharma Inc. for $1.75 billion, and Roche Holding AG's deal for InterMune Inc.